Background This study evaluated the efficacy of an intervention combining the Valencia
| INTRODUCTION
Pain, fatigue, and sleep difficulties are the most common symptoms reported by individuals with cancer. 1 Preliminary evidence supports the potential for non-pharmacological interventions in the management of cancer-related symptoms.
Evidence for the efficacy of cognitive-behavioral therapy (CBT) is strong enough to recommend it as first-line treatment for cancerrelated sleep problems. 2 Moreover, evidence from functional neuroimaging studies supports the use of hypnosis for pain management. 3 There is also evidence supporting the promise of hypnosis for managing cancer-related pain and other symptoms, [4] [5] [6] and the combination of CBT with hypnosis has shown to be effective for fatigue management in patients undergoing radiotherapy for breast cancer. 7, 8 A form of hypnosis, the Valencia model of waking hypnosis (VMWH), [9] [10] [11] [12] may be particularly suited for helping patients better manage symptoms in their daily life. It consists of several standardized methods intended to be efficient, easy to learn, and easy to use in everyday life situations. It is based on waking hypnosis, the primary characteristic of which is that patients are able to use self-hypnosis
with their eyes open, while engaged in other activities. This allows them to experience therapeutic suggestions whenever the need arises including current and (possible) future symptoms, using the VMWH exercises. 12, 16 Finally, during this intervention, participants received information about pain, fatigue, and sleep problems and learned behavioral strategies to cope with them during the study to facilitate the maintenance of treatment gains. The EC intervention consisted of four sessions of didactic lectures and discussions regarding their presenting symptoms, based on an education intervention used in a previous study, 17 adapted to the symptoms that were the focus of the study. Participants in both conditions received a handbook with readings and exercises. They were assigned home activities and encouraged to read the materials as often as they found it helpful (EC) or to practice the skills taught (VMWH-CBT) approximately 3 times per day between sessions. Treatments were based on manuals developed by the study clinician (M.E.M.) with input from another study investigator (M.P.J.). Each session lasted approximately 1 hour.
The VMWH-CBT treatment and EC manuals are available from the primary author (M.E.M.). All treatments were provided by the study clinician (M.E.M.).
| Measures

| Demographic and descriptive information
All participants provided demographic information and cancer history information (age, gender, marital status, and employment status; type of cancer and treatments).
| Primary outcome measures
Pain intensity was measured using 0-10 numerical rating scales of current pain and least, worst, and average pain during the past week.
Such 0-10 scales have demonstrated their validity and reliability as measures of pain by their strong association with other measures of pain intensity, responsivity to pain treatment, and stability over time without intervening treatment. 18 Fatigue was measured using the Patient-reported Outcomes Measurement Information System (PROMIS) 7-item fatigue short form, which has strong psychometric properties. 19 Participants rated how often they experienced each item on a 5-point scale ranging from 'never' to 'always' . As with all the PROMIS measures, the PROMIS Fatigue scores are reported on a T-score metric that is anchored to mean levels of each outcome in a healthy US general population. 20 Sleep problems were assessed using the 9-item Medical Outcomes Survey Sleep Problem Index. 21 The scale yields an Overall Sleep Problems Index, where higher scores indicate greater sleep impairment. There is support for the reliability and validity of the Medical Outcomes Survey Sleep measure. 22 
| Secondary outcome measures
Pain interference was measured using the 6-item PROMIS Pain
Interference Short Form, which assesses the impact of pain on various areas of functioning. 23 Scores are converted to T scores to be consistent with the PROMIS metric. This scale has demonstrated adequate psychometric characteristics. 23 Depressive symptoms were assessed with the Patient Health
Questionnaire Depression Scale (PHQ-8)
both a diagnostic and severity measure and has shown good psychometric properties in general and in patients with cancer. 25 Pain catastrophizing was measured using the Pain Catastrophizing Scale (PCS). 26 Participants indicate the degree to which they experienced each of 13 thoughts or feelings when experiencing pain.
A total PCS score of 30 indicate a clinically relevant level of catastrophizing. The PCS has adequate to excellent internal consistency and satisfactory validity.
Cancer and treatment distress was measured by the Cancer Treatment Distress Scale, 27 which has shown excellent psychometric properties. This scale consists of 22 items that assess how much distress or worry cancer or its treatment has caused in the past week.
| Procedures
Research assistants contacted individuals participating in previous studies who indicated an interest in being contacted about future studies and, if interested, screened them for eligibility. Also clinical oncology providers identified potentially eligible patients, suggested the study to them, and provided a brochure that included contact information for the study research assistants.
Eligible participants were randomly assigned to treatment order (ie, receiving the VMWH-CBT intervention first and then the EC intervention or vice versa). The randomization was blocked so that the allocation ratio was 1:1. The blocks had different sizes in different orders for each subgroup to prevent the study clinician (M.E.M.) from being able to predict the randomization order.
In order to avoid unblinding the research staff who collected outcome data, the clinician prepared the materials for the condition assigned to each participant after they had consented for participation.
The primary and secondary outcome measures were administered by phone by research assistants who were blind to the study hypotheses and treatment condition. Outcome measures were administered at pretreatment, after the first set of four treatments was completed, after the second set of four treatments, and at 3-month followup. The measures of descriptive/demographic information were administered at pretreatment only. Participants did not receive any compensation for participation, and all study procedures were approved by the University of Washington Institutional Review Board.
All participants provided signed informed consent.
| Data analyses
We first computed descriptive statistics for the demographic and can- 3 | RESULTS
| Recruitment and demographic characteristics
A total of 167 patients were identified as potential participants ( Figure 1 ). We were able to contact and screen 99 of these.
Forty-four (44.4% of those who were screened) were eligible and willing to participate, and were then randomized to receive the inter- she followed all the reading materials in English. Twelve (27.3%) of the participants withdrew from the study: 4 were unable to be contacted for follow-up assessments; and 8 withdrew during treatment. Reasons for attrition included the following: medical issues prevented them from attending the sessions (n = 3), having too many personal problems to be able to follow the program (n = 1), death (n = 1), moving to another state (n = 1), having to travel often overseas (n = 1), and wanting to pursue more therapy with more sessions (n = 1). Participants' demographic characteristics are presented in Table 1 . ranged from 42% to 64%, whereas for the EC intervention it ranged from 19% to 45%.
| Effects of the interventions on the outcome measures
With respect to the planned between-group comparisons in pretreatment to post-treatment changes in the primary outcomes, we found significantly greater improvements (P < .001) following active treatment, relative to the control condition, for sleep problems, fatigue, and average pain intensity. For the secondary outcome variables, significant between-groups differences emerged for depression (P < .001), cancer distress (P < .001), pain interference (P < .05), and pain catastrophizing (P < .05). Table 3 presents the means and standard deviations for the outcome measures at three time points for those participants who endorsed the symptoms at a level greater than 0: pretreatment, after the participant had received both treatments, and at 3-month follow-up. There is a significant time effect (P ≤ .001, Bonferroni adjusted) for all outcome measures except for pain interference.
| Maintenance of treatment gains on outcome measures
The significant changes are reported from pretreatment to posttreatment, and there are no significant changes from post-treatment to 3-month follow-up.
| DISCUSSION
The findings support the primary hypothesis that the VMWH-CBT intervention results in clinically significant greater improvements in pain, fatigue, and sleep problems than an EC intervention. The same effects were found in the secondary outcomes assessing depression, pain catastrophizing, cancer treatment distress, and pain interference.
The gains of the treatment in the primary and secondary outcomes This study has some important limitations. First, although the interventions were applied using a manual (ie, it was a highly standardized intervention), only one clinician, who was not blind to the hypotheses, provided both treatments to all the participants. Future studies should involve more clinicians when possible to control for the potential biasing effects of the therapist's skills and expectancies. In addition,
there were relatively few men in the sample. Thus, it is not clear if the findings would necessarily generalize to men with a history of cancer, although we know of no evidence suggesting that hypnotic or CBT approaches are more or less effective for women relative to men.
Moreover, the aim of this study was to investigate the clinical benefits of the VMWH treatment when combined with CBT. As a result, we
were not able to evaluate the relative contribution of each element to the overall benefits observed. Thus, further research is needed to identify the unique contributions of these treatment elements both alone and in combination and to evaluate their mechanisms. Finally, we did not measure expectancies for the treatments or evaluate the potential role of other mechanisms that could explain outcome (eg, brain activity, changes in self-efficacy). An important next step is to evaluate the role that such mechanism factors play in the benefits of this treatment.
Despite the study's limitations, the findings make important new contributions to our understanding of the potential for non- Means with different subscripts are significantly different from one another (P < .05, Bonferroni adjusted).
*P value for repeated measures ANOVA group by time interaction (P < .05, Bonferroni adjusted).
